Drug Profile
Talquetamab - Genmab/Janssen Research & Development
Alternative Names: GPRC5D/CD3-duobody-antibody-JNJ-64407564; JNJ 64407564; JNJ-7564; TALVEYLatest Information Update: 12 Feb 2024
Price :
$50
*
At a glance
- Originator Genmab; Janssen Research & Development
- Developer Janssen Research & Development
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Multiple myeloma
- Phase II Smoldering multiple myeloma
Most Recent Events
- 29 Jan 2024 Janssen Research & Development initiates the phase III MonumenTAL-6 trial in Multiple myeloma (Combination therapy) in Australia and South Korea (SC) (NCT06208150)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in Canada (SC, Injection)
- 19 Dec 2023 Janssen-Cilag plans the phase III MonumenTAL-6 trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, England, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Multinational, Netherlands, Poland, Saudi Arabia, Scotland, Spain, Sweden, Turkey, United Kingdom, USA, Wales (SC) (ISRCTN74178658)